Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells $41,800.00 in Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 836 shares of the company’s stock in a transaction on Monday, March 31st. The shares were sold at an average price of $50.00, for a total value of $41,800.00. Following the sale, the director now owns 278,109 shares of the company’s stock, valued at approximately $13,905,450. This trade represents a 0.30 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Pro-Dex Stock Performance

NASDAQ:PDEX traded up $1.35 during mid-day trading on Monday, hitting $49.58. 28,636 shares of the company traded hands, compared to its average volume of 22,246. The company has a quick ratio of 1.44, a current ratio of 2.58 and a debt-to-equity ratio of 0.33. The stock’s fifty day moving average price is $40.31 and its 200-day moving average price is $40.26. The firm has a market cap of $161.68 million, a price-to-earnings ratio of 24.67 and a beta of 0.68. Pro-Dex, Inc. has a one year low of $16.84 and a one year high of $59.60.

Pro-Dex (NASDAQ:PDEX) last announced its quarterly earnings data on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.23. Pro-Dex had a return on equity of 21.68% and a net margin of 11.06%. Research analysts anticipate that Pro-Dex, Inc. will post 2 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, StockNews.com downgraded shares of Pro-Dex from a “buy” rating to a “hold” rating in a report on Wednesday, March 12th.

Institutional Trading of Pro-Dex

A number of hedge funds and other institutional investors have recently modified their holdings of PDEX. FMR LLC lifted its stake in shares of Pro-Dex by 34.9% during the 3rd quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock valued at $119,000 after buying an additional 1,028 shares in the last quarter. Bank of New York Mellon Corp bought a new stake in Pro-Dex during the fourth quarter valued at about $202,000. Trexquant Investment LP purchased a new position in shares of Pro-Dex in the fourth quarter valued at about $252,000. Integrated Quantitative Investments LLC bought a new position in shares of Pro-Dex in the fourth quarter worth about $254,000. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in shares of Pro-Dex during the fourth quarter worth about $255,000. 15.28% of the stock is owned by hedge funds and other institutional investors.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.